In the field of cancer immunotherapy, CAR-T cells engineered to co-express CX3CR1 (NKG2D-CX3CR1 CAR-T) have been shown to enhance tumor infiltration and antitumor efficacy, demonstrating robust therapeutic effects, especially in tumor models with high CX3CL1 expression [122]. This evidence concerns the gene CX3CL1 and neoplasm.